Neoadjuvant Atezolizumab in Cutaneous Melanoma

Part of paid clinical trials in Houston, Texas.

Sponsor
The Methodist Hospital Research Institute
Study ID
NCT04020809
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Cutaneous Melanoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the body (non-metastatic) and can be removed by surgery (resectable) but has a higher risk of coming back after surgery (high-risk).

Key Dates

Start date
Sep 25, 2020
Status verified
Oct 2025
Primary completion
Oct 1, 2025
Completion
Oct 1, 2026

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Atezolizumab
    Atezolizumab will be administered as 1200 mg intravenously on Day 1 every 3 weeks for 2 cycles.

Primary Outcome Measure

Number of participants completing neoadjuvant atezolizumab [ Time Frame: 63 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Houston Methodist HospitalHoustonTexas77030-

Find similar trials in Houston, TX

By research site
Houston Methodist Hospital· Houston, TX

Related Studies